Production (Stage)
IN8bio, Inc.
INAB
$3.08
-$1.09-26.14%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.69M | 2.63M | 2.73M | 3.53M | 3.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.66M | 6.22M | 6.04M | 8.69M | 8.65M |
| Operating Income | -5.66M | -6.22M | -6.04M | -8.69M | -8.65M |
| Income Before Tax | -5.55M | -6.16M | -7.09M | -8.63M | -8.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.55M | -6.16M | -7.09M | -8.63M | -8.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.55M | -6.16M | -7.09M | -8.63M | -8.56M |
| EBIT | -5.66M | -6.22M | -6.04M | -8.69M | -8.65M |
| EBITDA | -5.16M | -5.74M | -5.56M | -8.26M | -8.20M |
| EPS Basic | -1.99 | -2.40 | -4.49 | -5.74 | -5.93 |
| Normalized Basic EPS | -1.25 | -1.50 | -2.38 | -3.59 | -3.71 |
| EPS Diluted | -2.10 | -2.40 | -4.49 | -5.74 | -6.00 |
| Normalized Diluted EPS | -1.25 | -1.50 | -2.38 | -3.59 | -3.71 |
| Average Basic Shares Outstanding | 2.78M | 2.57M | 1.58M | 1.50M | 1.44M |
| Average Diluted Shares Outstanding | 2.78M | 2.57M | 1.58M | 1.50M | 1.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |